Karim Atta

Karim Atta

Auto-generated profile, based on publicly available information

Karim Atta

Institute of Medicine, National Research Mordovia State University, Saransk, Russia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2026 in World Journal for Pediatric and Congenital Heart Surgery
Verified
Journal Article
Closed access
KAKarim Atta
Karim Atta
AAAbdelaziz Abdelaziz
Abdelaziz Abdelaziz
SRShrouk Ramadan
Shrouk Ramadan
AGAhmed Farid Gadelmawla
Ahmed Farid Gadelmawla
MMMohamed R. Murad
Mohamed R. Murad
ESElena Semenovna Samoshkina
Elena Semenovna Samoshkina
Background: Congenital aortic valve stenosis (AVS) is the most common cause of ventricular outflow tract obstruction. Surgical aortic valvuloplasty (SAV) and balloon aortic valvuloplasty (BAV) are the most common primary interventions, with conflicting data regarding their long-term outcomes. We aimed to study the long-term clinical outcomes of patients allocated to BAV or SAV. Methods: We searched PubMed, Scopus, Web of Science, and Cochrane CENTRAL through August 2025 for relevant studies reporting long-term outcomes of SAV versus BAV in patients with congenital AVS. The primary outcome was the 10-year rate of aortic valve replacement (AVR). Subgroup analysis was performed for all clinical outcomes according to the age of the included children. Results: A total of nine trials including 1704 patients (67%, [1136/1704]) males; median follow-up of 10 years) were included. The pooled estimate showed that SAV was associated with lower long-term reintervention rates (risk ratio 0.76, 95% confidence interval (CI): 0.6 to 0.96, P = .02), and a significant reduction in peak aortic gradient pressure (PAGP) (mean difference (MD) −11.53 mm Hg, 95% CI: −18.66 to −4.41, P < .001) in patients more than 1 year of age. In addition, SAV was associated with a longer time to first reintervention in patients younger than 1 year of age (MD 2.43 years, 95% CI: 0.68 to 4.19, P = .01). There was no significant difference regarding the primary outcome or other studied outcomes. Conclusion: In patients with congenital aortic valve stenosis, SAV showed the greatest benefit in children older than 1 year of age with similar AVR and mortality rates; but superior durability, lower reintervention rates, and greater reductions in peak aortic pressure gradient when compared with BAV.

31 March 2026 in Medicine and Biotechnology
Verified
Journal Article
Open access
PDF file
KAKarim Aly Zaky Atta
Karim Aly Zaky Atta
VDVasily I. Davydkin
Vasily I. Davydkin
MAMohamed Saed Mohamed AbdelAziz
Mohamed Saed Mohamed AbdelAziz
ASAhmed Mohamed Fathy Sobhy
Ahmed Mohamed Fathy Sobhy
AAAbdelaziz Abdelaziz
Abdelaziz Abdelaziz
Introduction. Beta-blockers are commonly prescribed after myocardial infarction; however, their benefit in patients without heart failure and with preserved left ventricular ejection fraction in the modern era of reperfusion therapy remains unclear. The aim of the study is to evaluate the effect of beta-blockers on clinical outcomes in patients without heart failure.Materials and methods. The authors conducted a systematic review and meta-analysis of randomized controlled trials evaluating beta-blocker therapy after discharge in patients with myocardial infarction without clinical manifestations of heart failure. Searches in PubMed, Scopus, Web of Science, and Cochrane CENTRAL were performed in February 2026. The primary outcome was major adverse cardiovascular and cerebrovascular events. Secondary outcomes included mortality, recurrent myocardial infarction, heart failure, revascularization, and stroke. Hazard ratios with 95% confidence intervals were pooled using a random-effects model.Results. Four randomized controlled trials including 19,826 patients were analyzed. Beta-blocker therapy was not associated with a significant reduction in the incidence of major adverse cardiovascular and cerebrovascular events (hazard ratio 0.98, 95% confidence interval: 0.91–1.06, p = 0.64) or any of the secondary outcomes: all-cause mortality (hazard ratio 0.98, 95% confidence interval: 0.85–1.13, p = 0.78), recurrent myocardial infarction (hazard ratio 0.88, 95% confidence interval: 0.72–1.07, p = 0.20), heart failure (hazard ratio 0.82, 95% confidence interval: 0.63–1.07, p = 0.14), revascularization (hazard ratio 1.01, 95% confidence interval: 0.87–1.17, p = 0.86), or stroke (hazard ratio 1.24, 95% confidence interval: 0.97–1.59, p = 0.09). Discussion and conclusion. In patients with acute myocardial infarction without heart failure and with preserved left ventricular function, routine beta-blocker therapy after discharge was not associated with a reduction in the incidence of major adverse cardiovascular and cerebrovascular events or their individual components in the context of contemporary reperfusion therapy. Further large-scale studies are required to develop individualized therapeutic approaches.

5 October 2026 in European Journal of Internal Medicine
Verified
Journal Article
Closed access
BHBelal Mohamed Hamed
Belal Mohamed Hamed
KAKarim Atta
Karim Atta
AEAhmed Emara
Ahmed Emara
MAMoaz Elsayed Abouelmagd
Moaz Elsayed Abouelmagd
YSYasar Sattar
Yasar Sattar